AbbVie (ABBV) exec. says they anticipate aesthetics growth will remain challenged in 2026 and are focused on investing to stimulate the market

• Expects 2026 Skyrizi revenue of USD 21.5bln and Rinvoq revenue of USD 10bln.
• Expects 2026 revenue of aesthetic sales to reach USD 5bln including Botox cosmetic revenue of USD 2.7bln.
• Expects Q1 adj. EPS between 2.97-3.01 (exp. 3.07); Net revenue approx. 14.7bln (exp. 14.85bln).

AbbVie anticipates challenges in its aesthetics growth through 2026, which could weigh on investor sentiment, especially as they plan to invest in stimulating the market. The expected revenue figures, particularly for Skyrizi and Rinvoq, imply a continued focus on their core therapeutic markets, but the slight miss on Q1 EPS and net revenue relative to expectations may raise some eyebrows about their overall outlook. Traders should watch how these developments influence market perception and stock performance, particularly in relation to competitors in the biotech space.